Total trials
75
Active
27
Phase 3
1
Total enrollment
23,839
Pipeline matrix
Showing 15 of 15 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Exome analysis | — | — | — | — | — | 1 | |
| Phase I - Mirdametinib - Level 1 | — | — | — | — | — | 1 | |
| Phase II - Mirdametinib | — | — | — | — | — | 1 | |
| Phase I - Mirdametinib - Level 2 | — | — | — | — | — | 1 | |
| Phase I - Mirdametinib - Level 3 | — | — | — | — | — | 1 | |
| Phase I - Mirdametinib - Level 4 | — | — | — | — | — | 1 | |
| FOLFIRINOX Bevacizumab | — | — | — | — | — | 1 | |
| FOLFIRINOX treatment | — | — | — | — | — | 1 | |
| trifluridine/tipiracil + XB2001 | — | — | — | — | — | 1 | |
| trifluridine/tipiracil + placebo | — | — | — | — | — | 1 | |
| Lipidomic analyses | — | — | — | — | — | 1 | |
| olaparib, durvalumab, tremelimumab | — | — | — | — | — | 1 | |
| Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab | — | — | — | — | — | 1 | |
| blood sample | — | — | — | — | — | 3 | |
| With non-magnetic screen | — | — | — | — | — | 1 |
Next readouts
- 2023-01-16
- 2025-09-27
- 2026-10-13
- 2027-05-01
- 2027-08-10
- 2028-04-07
- 2028-07-25
- 2028-09-02
- 2029-07-24
- 2030-06-01
Top conditions
- Breast Cancer11
- Cancer6
- Metastatic Colorectal Cancer4
- Colorectal Cancer3
- Glioblastoma3
- Prostate Cancer3
- Genetic Predisposition2
- Non-Small Cell Lung Cancer2
Frequently asked questions about Centre Georges Francois Leclerc
- How many clinical trials does Centre Georges Francois Leclerc have on ClinicalTrials.gov?
- Centre Georges Francois Leclerc is listed as the lead sponsor on 75 clinical trials in ClinicalTrials.gov, 27 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Centre Georges Francois Leclerc's trials are in Phase 3?
- 1 of Centre Georges Francois Leclerc's trials are in Phase 3, spread across 15 active drug programs.
- What therapeutic areas does Centre Georges Francois Leclerc focus on?
- Centre Georges Francois Leclerc's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Cancer, Metastatic Colorectal Cancer, Colorectal Cancer, Glioblastoma.
- When are Centre Georges Francois Leclerc's next clinical trial readouts?
- Centre Georges Francois Leclerc has 10 upcoming primary-completion readouts tracked here; the soonest is “Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)”, expected around 2023-01-16.